What's Happening?
Scientists at Rockefeller University's Laboratory of Molecular Metabolism, in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) researchers, have discovered that losartan, a common blood pressure medication, enhances brown adipose tissue
(BAT) activity and metabolism in mice. This finding, published in Nature, suggests that repurposing losartan could be a viable method to stimulate brown fat, which has been linked to improved cardiovascular health and, as a new finding in this study, psychiatric health. The research utilized a reverse translational approach, analyzing medical records and PET/CT scans from over 100,000 patients to identify connections between brown fat presence and various health outcomes. They found that individuals with more brown fat had significantly lower odds of cardiometabolic diseases. Further analysis revealed that patients taking angiotensin receptor blockers (ARBs), including losartan, had a higher presence of brown fat. Experiments with cultured brown fat cells and healthy mice confirmed that losartan directly increased metabolic activity, independent of its blood pressure-lowering mechanisms.
Why It's Important?
This discovery holds significant implications for public health, particularly in the U.S., where cardiometabolic diseases like coronary artery disease and type II diabetes are prevalent. By repurposing an existing drug with a known safety profile, the path to new treatments could be accelerated. The potential to stimulate brown fat, which is associated with better glycemic parameters, lipid profiles, and lower inflammatory markers, could offer a novel therapeutic strategy for these conditions. Furthermore, the unexpected link between brown fat and improved psychiatric health, including a lower incidence of anxiety and depression, opens new avenues for understanding and treating mental health disorders. This could lead to integrated treatment approaches that address both physical and mental well-being, potentially reducing the burden of these interconnected health issues on the U.S. healthcare system.
What's Next?
The findings suggest several future research directions. Scientists plan to investigate the genetics of individuals with high levels of brown adipose tissue and further explore the connection between brown fat and anxiety and depression. They will also examine potential downsides associated with brown fat, such as higher rates of osteoporosis and skin diseases, which were observed in some individuals with BAT. Additionally, the research team intends to investigate other medications that were associated with brown fat activity in their large patient cohort, beyond losartan. The goal is to identify additional drugs that could be repurposed to stimulate brown fat, potentially leading to new therapies that can be isolated to stimulate brown fat without affecting blood pressure, allowing for broader application in individuals with normal blood pressure.
Beyond the Headlines
The study's use of a reverse translational approach, moving from clinical observations to molecular underpinnings, highlights an evolving paradigm in medical research. This method, leveraging large datasets and machine learning, allows for the identification of unexpected correlations that can then be rigorously tested in laboratory settings. The finding that losartan's metabolic effects are distinct from its blood pressure-lowering properties is crucial, as it suggests the possibility of developing targeted therapies that can stimulate brown fat without altering blood pressure, thereby expanding the potential patient population. The observed dampening effect of SSRIs on brown fat activity also raises intriguing questions about the complex interplay between metabolic health, mental health, and pharmacological interventions, suggesting a need for a more holistic understanding of drug effects on the body's interconnected systems.
